First Horizon Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

First Horizon Advisors’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$2.73K	Sell	24 -11	-31%	-$1.18K	﹤0.01%	1976
2025 Q1	$3.68K	Sell	35 -32	-48%	-$3.62K	﹤0.01%	1864
2024 Q4	$7.18K	Hold	67	–	–	﹤0.01%	1715
2024 Q3	$6.71K	Hold	67	–	–	﹤0.01%	1735
2024 Q2	$5.64K	Buy	67 +35	+109%	+$2.79K	﹤0.01%	1725
2024 Q1	$2.34K	Buy	+32	New	+$2.36K	﹤0.01%	1992
2022 Q3	–	Sell	-11	Closed	-$1K	–	2373
2022 Q2	$1K	Buy	+11	New	+$624	﹤0.01%	2225
2020 Q3	–	Sell	-10	Closed	–	–	1485
2020 Q2	$0	Sell	10 -11	-52%	-$697	﹤0.01%	1431
2020 Q1	$0	Sell	21 -243	-92%	-$13.8K	﹤0.01%	1479
2019 Q4	$17K	Hold	264	–	–	﹤0.01%	915
2019 Q3	$16K	Sell	264 -106	-29%	-$6.66K	﹤0.01%	926
2019 Q2	$26K	Buy	+370	New	+$27.3K	﹤0.01%	781

Other funds holding LGND

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Horizon Advisors's LGND Position: Q2 2025 in Review

First Horizon Advisors reduced its Ligand Pharmaceuticals (LGND) stake by 31% in Q2 2025, selling an estimated $1.18K and leaving 24 shares worth $2.73K. The position accounts for ﹤0.01% of the portfolio, ranked #1976.

First Horizon Advisors first reported a position in LGND in Q2 2019 and has held it in 12 quarters since. The position peaked at $26K in Q2 2019. 271 funds tracked by Wall St. Rank hold LGND as of Q2 2025.

First Horizon Advisors held 24 shares of Ligand Pharmaceuticals worth $2.73K as of Q2 2025.
First Horizon Advisors sold 11 Ligand Pharmaceuticals shares in Q2 2025, an estimated $1.18K.
Ligand Pharmaceuticals made up ﹤0.01% of First Horizon Advisors's portfolio in Q2 2025, its #1976 holding.
First Horizon Advisors first reported a position in Ligand Pharmaceuticals in Q2 2019 and has held it in 12 quarters since.
First Horizon Advisors's Ligand Pharmaceuticals position peaked at $26K in Q2 2019.
271 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2025.

Based on First Horizon Advisors's 13F filing for Q2 2025, filed 6 Aug 2025.